Slide 1: Investor Relations
Investor Relations August 1, 2023
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of federal securities laws. These forward-looking statements include statements with respect to 2023 guidance, strategic and growth opportunities, other expectations and other non-historical informa
Slide 3: Our Mission and Our Vision
Our Mission Be the clinician’s most trusted partner for medication management. We are dedicated to continuously deliver innovative technology that helps our customers improve patient care, for everyone. Our Vision Deliver the most compelling automation and services that accelerate pharmacy perfectio
Slide 4: Our Strategy
Our Strategy Fundamentally transform the pharmacy care delivery model by delivering a set of services that touch the entire continuum of care, built on a single cloud platform. © 2023 Omnicell, Inc. 4
Slide 5: Omnicell: Compelling Growth Opportunities
Omnicell: Compelling Growth Opportunities 1 2 3 4 Category creator Leading strategic partner to Resilient, long-term revenue Demonstrated track record of transforming the pharmacy health systems in large and growth accelerated by strong growth built on a platform of care delivery model growing marke
Slide 6: The Autonomous Pharmacy Framework – an Industry Vision
1 The Autonomous Pharmacy Framework – an Industry Vision Level 5 Intermediate Autonomous Pharmacy Majority of processes automated, Fully with barcode tracking applied widely Autonomous Pharmacy Limited Autonomous Pharmacy Data integrated across enterprise and mostly visible Level 4 Complete process
Slide 7: Our Comprehensive Solutions Fundamentally Deliver Better Healthcare Value
1 Our Comprehensive Solutions Fundamentally Deliver Better Healthcare Value Central Pharmacy Inventory Dispensing Service Optimization Service IV Compounding Specialty Central Inventory Service Distribution Management Pharmacy Services IV Compounding Retail Point of EnlivenHealth® Care Point of Conn
Slide 8: Leader in Large and Growing Segments
2 Leader in Large and Growing Segments Omnicell is growing its leadership position across a potential $90 Billion+ TAM Estimated TAM Opportunity1 $22 Billion $19 Billion Retail Point of Care $90 Billion+ TOTAL TAM $19 Billion $32 Billion Specialty Pharmacy Services Central Pharmacy © 2023 Omnicell,
Slide 9: Revenue Growth Drivers
3 Revenue Growth Drivers Deep Customer • Strong position within the top 300 U.S. health systems Relationships & • Robust backlog of $1.215 Billion as of 12/31/2022 Robust Backlog • Customers increasingly turning to Omnicell for our platform-based approach to medication management Multiple Growth • E
Slide 10: Advanced Services Accelerating Recurring Revenue Growth
3 Advanced Services Accelerating Recurring Revenue Growth Leveraging established channels Advanced Services and strong customer relationships (% of Total Revenue) Strong demand driven by increasing Targeting 18% of total revenue for 2023 provider digitization and need to evolve medication supply cha
Slide 11: Advanced Services Business Model — Customer Example
3 Advanced Services Business Model — Customer Example Tech-Enabled Services Model (IVCS and CPDS) YEAR 1 YEAR 2 YEAR 3 YEAR 4 – 7 Product Revenue End of year 7 Cash Cash Cash Cash Recurring Advanced Received Received Received Received Net sales type lease Services balance: $0 Revenue Recurring Advan
Slide 12: Strong Balance Sheet
4 Strong Balance Sheet $2,194M Free cash flow projected $1,164M to grow slower than $1,016M EBITDA as Omnicell reinvests in the $554M $399M transformation to $32M Advanced Services Cash and Cash Equi valents Total Assets Total Equity Liquidity and capital 1.9x structure support growth strategy 1.1x
Slide 13: Backlog ($Million)
Backlog1 ($Million) By type: As of December 31, 2022 As of December 31, 2021 Product Backlog $797 $977 Advanced Services Backlog2 $418 $277 Total Backlog $1,215 $1,254 By duration and type: As of December 31, 2022 As of December 31, 2021 Short-Term Product Backlog $503 $745 Long-Term Product Backlog
Slide 14: Total Year Revenue Composition
Total Year Revenue Composition Year over Recurring vs Updated YoY Actual Year Actual YoY Actual YoY GAAP ($Million) Non Category Guidance Change % TY-2020 (YoY) TY-2021 Change % TY-2022 Change % Recurring TY-2023 (Mid-Point) Change % Connected Devices, Software Licenses, Non 1 Product $560 -2% $739
Slide 15: Financial Snapshot
Financial Snapshot Q2-2023 Results YoY Change % Total Revenues $299 Million -10% Non-GAAP Gross Margin % 46.8% -270bps Non-GAAP Operating Expenses $108 Million -10% Non-GAAP EBITDA $47 Million -16% Non-GAAP Diluted Earnings Per Share $0.57 -32% See Appendix for a reconciliation of Q2-2023 Non-GAAP G
Slide 16: Updated 2023 Guidance
Updated 2023 Guidance Long-Term Value Creation Opportunities Leadership position in the digital Q3-2023 TY-2023 transformation of healthcare with $90 Billion+ TAM3 Bookings1 Not Provided $1.000-$1.100 Billion2 Emerging and scaling of Advanced Services offerings Total Revenues $290-$300 Million $1.16
Slide 17: A Better Way: Our ESG and Innovation Strategy
A Better Way: Our Environment, Social, Governance, and Innovation Strategy Environment Governance Innovating for Energy Efficiency Doing the Right Thing Actively contribute to realize 1.5° Identify, prevent, and mitigate risk Celsius future by 2030 to Omnicell to create, preserve, and realize value
Slide 18: A Better Way: Our Approach to ESG
A Better Way: Our Approach to ESG Our Approach Omnicell uses a risk-based approach designed to strategically align our ESG goals and targets to address the risks we believe are most material to our organization In 2021, Omnicell identified 11 material topic areas that our internal and external stake
Slide 19: A Better Way: ESG in Action
A Better Way: ESG in Action Environment Social 2022 ESG • Decreased Scope 1 and 2 emissions in 2022 by 17% from 2021 • Finalized creation of four Employee Resource Groups and established a Global Culture Report Committee • Conducted a Climate Risk Assessment to Published third annual ESG identify to
Slide 20: We Expect that Omnicell is Positioned to Win
We Expect that Omnicell is Positioned to Win Based on Our Belief that: Omnicell has the right Omnicell is positioned as Omnicell is scaling With a track record of solutions and the right the leading strategic Advanced Services to strong financial business model to solve partner to health capitalize
Slide 21: Appendix
Appendix
Slide 22: Reconciliation of GAAP to Non-GAAP
Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Three Months Ended June 30, 2023 2022 Reconciliation of GAAP revenues to non-GAAP revenues: GAAP revenues $ 298,973 $ 331,386 Acquisition accounting impact related to deferred revenues —
Slide 23: Reconciliation of GAAP to Non-GAAP
Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Three Months Ended June 30, 2023 2022 Reconciliation of GAAP income from operations to non-GAAP income from operations: GAAP income from operations $ 7,748 $ 12,485 GAAP operating income
Slide 24: Reconciliation of GAAP to Non-GAAP
Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Three Months Ended June 30, 2023 2022 Reconciliation of GAAP net income per share - diluted to non-GAAP net income per share - diluted: Shares - diluted GAAP 45,472 46,260 (b) Shares - d
Slide 25: Reconciliation of GAAP to Non-GAAP: EBITDA
Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Three Months Ended June Three Months Ended Three Months Ended Three Months Ended Year Ended 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 December 31, 2017 (a) Reconciliat
Slide 26: Reconciliation of GAAP to Non-GAAP: Net Debt and Liquidity
Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Quarter Ended June 30, Quarter Ended June 30, 2023 2023 Convertible senior notes, net $ 568,114 Revolver availability $ 417,687 Cash and cash equivalents (399,464) Cash and cash equivale
Slide 27: Slide 27